SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

March 8, 2024

https://www.globenewswire.com/news-release/2024/03/08/2843039/0/en/SciSparc-Announces-Enrollment-of-First-Patient-for-its-Clinical-Trial-for-Children-with-Autism-Spectrum-Disorder.html

TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the first patient has been enrolled in the Company’s clinical trial assessing the efficacy and safety of SCI-210 for the treatment of children with autism spectrum disorder (“ASD”) between the ages of 5 and 18.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.